Table 1.
-bafilomycin | +bafilomycin | |
---|---|---|
BWP17+CIp30 | 0.2173 ± 0.0010 | 0.1745 ± 0.0009∗ |
Δ878 | 0.2214 ± 0.0010 | 0.2117 ± 0.0013∗ |
Δ866 | 0.2170 ± 0.0009 | 0.1979 ± 0.0007∗ |
Δ864 | 0.1792 ± 0.0008 | 0.1675 ± 0.0009∗ |
Δ862 | 0.1947 ± 0.0009 | 0.1914 ± 0.0009∗ |
Δ858 | 0.1306 ± 0.0011 | 0.1311 ± 0.0008 |
Growth rates with and without the V-ATPase specific inhibitor bafilomycin were measured in Pma1p truncation mutants by growing cells in CSM with 2% glucose in a plate reader with OD600 readings taken at 15 min intervals. Growth curves were analyzed using Graphpad Prism: first, curves were fitted using a Weibull growth model (Weibull, 1951). Then, calculated growth rates were analyzed two-way ANOVA, as appropriate, followed by multiple-comparison post-tests. Data represents the average values of three independent experiments. Addition of bafilomycin did not reduce growth in the Δ858 strain (truncated by 38 aa, respectively). ∗Indicate statistical significance compared to the growth rate of the same strain without bafilomycin.